Go online to PeerView.com/RGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although the prognosis of patients with early breast cancer (EBC) has improved with earlier detection and more efficacious therapies, many patients still face poor outcomes, and there is an urgent need to prevent recurrences. An increasing number of systemic therapies have been recently approved in the perioperative settings of HR+, HER2+, and triple-negative breast cancer (TNBC), including immunotherapy, CDK4/6 inhibitor therapy, adjuvant PARP inhibitor therapy, and a number of HER2-targeted therapies. Other agents and combinations are undergoing evaluation in clinical trials and are likely to expand the systemic therapy arsenal for patients with EBC. With the increasing complexity of systemic and local treatment of patients with EBC, it is crucial for surgeons, medical oncologists, pathologists, and other members of the breast cancer care team to effectively collaborate and coordinate management strategies to ensure optimal treatment selection and planning with longer-term goals in mind. This PeerView educational activity, based on a recent live symposium, provides an overview of the essential evidence supporting the use of a growing number of perioperative systemic therapies for patients with different subtypes of EBC. Optimally integrating these therapies into practice with multidisciplinary collaboration is demonstrated through the use of case scenarios, highlighting the nuances of applying new data to clinical decision-making. Upon completion of this activity, participants should be better able to: Analyze the latest evidence and guidelines supporting the use of standard-of-care and novel/emerging therapies for different subtypes of early-stage breast cancer and their role as part of multimodal treatment plans; Apply best practices for multidisciplinary risk assessment and predictive/prognostic testing to inform treatment planning for patients with different subtypes of early-stage breast cancer; and Implement multidisciplinary and patient-centric strategies for shared decision-making to ensure the development and implementation of optimal, individualized treatment plans in different settings of early-stage breast cancer.